Intelligence Feed event · Policy · 2026-10-11

    Viking Therapeutics Advances Oral Obesity Candidate VK2735 to Phase 3 Clinical Testing

    Question

    Viking Therapeutics Advances Oral Obesity Candidate VK2735 to Phase 3 Clinical Testing

    Direct answer

    Viking Therapeutics has moved its oral obesity drug VK2735 into Phase 3 testing following Phase 2 trial results demonstrating average weight reductions of 12.2%. The asset enters late-stage development against established pharmaceutical competitors, notably Eli Lilly, where trial data on oral candidates like Foundayo has shown lower patient discontinuation rates and stronger gastrointestinal tolerability.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-11
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Viking Therapeutics Advances Oral Obesity Candidate VK2735 to Phase 3 Clinical Testing”, revision 1, evidence through 2026-10-11. https://marketontology.com/market-events/2026-10-11/viking-therapeutics-advances-oral-obesity-candidate-vk2735-to-phase-3-clinical-t-0fc0a0

    POLICY
    Viking Therapeutics Advances Oral Obesity Candidate VK2735 to Phase 3 Clinical Testing
    Viking Therapeutics has moved its oral obesity drug VK2735 into Phase 3 testing following Phase 2 trial results demonstrating average weight reductions of 12.2%. The asset enters late-stage development against established pharmaceutical competitors, notably Eli Lilly, where trial data on oral candidates like Foundayo has shown lower patient discontinuation rates and stronger gastrointestinal tolerability.
    VKTXLLY
    Impact
    72
    OCT 11
    SIG
    85%
    VKTXLLY
    Viking Therapeutics Advances Oral Obesity Candidate VK2735 to Phase 3 Clinical Testing
    Viking Therapeutics has moved its oral obesity drug VK2735 into Phase 3 testing following Phase 2 trial results demonstrating average weight reductions of 12.2%. The asset enters late-stage development against established pharmaceutical competitors, notably Eli Lilly, where trial data on oral candidates like Foundayo has shown lower patient discontinuation rates and stronger gastrointestinal tolerability.
    → Phase 3 trial initiation for VK2735 establishes clinical trial timeline milestones, determining competitive positioning against LLY in the oral GLP-1 and dual-agonist obesity market.
    Impact
    Viking Therapeutics has moved its oral obesity drug VK2735 into Phase 3 testing following Phase 2 trial results demonstrating average weight reductions of 12.2%. The asset enters late-stage development against established pharmaceutical competitors, notably Eli Lilly, where trial data on oral candidates like Foundayo has shown lower patient discontinuation rates and stronger gastrointestinal tolerability.
    Affected
    VKTXLLY
    Transmission
    Phase 3 trial initiation for VK2735 establishes clinical trial timeline milestones, determining competitive positioning against LLY in the oral GLP-1 and dual-agonist obesity market.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    VKTXlate-stage clinical pipeline progression and regulatory valuation de-riskingUp1-3mSource explicitly notes Viking Therapeutics advancing oral VK2735 to Phase 3 testing.
    LLYoral incretin market share defense and clinical differentiationWatch1-3mSource directly contrasts VK2735 with Eli Lilly's Foundayo.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    LLYWatch1188.72 2026-10-07PendingPendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month